Literature DB >> 3529410

Fulminant and subfulminant liver failure: definitions and causes.

J Bernuau, B Rueff, J P Benhamou.   

Abstract

Fulminant or subfulminant liver failure, complicated by encephalopathy and in many cases by death is seen to be a syndrome that may result from numerous causes. Although viral hepatitis, drug-induced hepatitis, and hepatitis due to various types of poisonings, in decreasing frequency, account for 90% of all cases, a variety of miscellaneous conditions account for the remainder. Consideration of the possibility of these less common etiologies by the clinician is of considerable importance, since some, including massive malignant involvement (such as leukemia) or acute fulminant Wilson's disease, may respond to specific treatment measures. Thus, unless hepatic transplantation proves to be applicable in FHF of many etiologic diagnosis may continue to have important therapeutic indications in at least some cases with this syndrome.

Entities:  

Mesh:

Year:  1986        PMID: 3529410     DOI: 10.1055/s-2008-1040593

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  105 in total

1.  Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

Authors:  L Spahr; L Rubbia-Brandt; P R Burkhard; F Assal; A Hadengue
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Bioartificial liver support for fulminant hepatic failure.

Authors:  Robert S Brown; Howard J Worman
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

3.  Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure.

Authors:  Marius John-Marc Ilario; Hach Vladimir Turyan; Constantine A Axiotis
Journal:  Virchows Arch       Date:  2003-04-26       Impact factor: 4.064

4.  Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine.

Authors:  F Durand; J Bernuau; E Giostra; G Mentha; D Shouval; C Degott; J P Benhamou; D Valla
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

5.  Hepatic steatosis prevents heme oxygenase-1 induction by isoflurane in the rat liver.

Authors:  Patrick Stoll; Christian I Schwer; Ulrich Goebel; Hartmut Buerkle; Alexander Hoetzel; Rene Schmidt
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

6.  A rare case of severe acute hepatitis associated with adult-onset still disease dramatically improved by high-dose steroid therapy.

Authors:  Tiffany Hogan; Kevin T Kao; Jim Tung
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 7.  Fulminant hepatic failure. Clinical features, etiology, epidemiology, and current management.

Authors:  L Capocaccia; M Angelico
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

8.  Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B.

Authors:  Fang-Yuan Gao; Yao Liu; Xiao-Shu Li; Xie-Qiong Ye; Le Sun; Ming-Fan Geng; Rui Wang; Hui-Min Liu; Xiao-Bing Zhou; Li-Li Gu; Yan-Min Liu; Gang Wan; Xian-Bo Wang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 9.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

10.  16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection.

Authors:  M Abecassis; J A Falk; L Makowka; V J Dindzans; R E Falk; G A Levy
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.